News for PPD, Inc. (PPD)

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. ”œWe delivered s

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. ( SAGE) (”œSage”) on behalf of

We recently published a list of the 10 Best Chinese Stocks to Buy According to Billionaires. In this article, we are going to take a look at where PDD Holdings Inc.

PR NewswireSALT LAKE CITY, March 13, 2025 SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveragi

Sage Therapeutics, Inc. (Nasdaq: SAGE) (”œSage” or ”œthe Company”), today announced that its Board of Directors has initiated a process to explore strate

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at t

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Centessa Pharmaceuticals appoints new Chief Medical Officer

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

**media[458934]**

Earnings call: Enel Chile's robust hydro generation boosts 2024 performance

Earnings call: Biogen reports progress and strategic pipeline expansion

LOS ANGELES, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses The Portnoy...

Earnings call: Thermo Fisher raises EPS guidance amid steady growth

Lipocine reports promising oral brexanolone study results

We’ve completed ten quarters since the launch of Kingdom Capital Advisors. Read more here.

Lipocine announces positive bioequivalence study results

Lipocine reports bioequivalence in oral PPD treatment study

Washington, DC and New York, NY - Global investment firm Carlyle made a leadership announcement within Americas Corporate Private Equity, part of its Global Private Equity segment,...